{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:26:12Z","timestamp":1793913972965,"version":"4.8.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.eprac.2026.08.031","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:56:44Z","timestamp":1792079804000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Using Homeostatic Model Assessment of Insulin Resistance to Improve Metabolic Dysfunction-Associated Steatotic Liver Disease Risk Stratification in Individuals With Type 2 Diabetes From Primary Care and Endocrinology Settings"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3601-0078","authenticated-orcid":false,"given":"Nathaly","family":"Cuervo-Pardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srilaxmi","family":"Kalavalapalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9936-0206","authenticated-orcid":false,"given":"Eddison","family":"Godinez Leiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ortiz Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Barb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Bril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margery A.","family":"Connelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Grajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Perdomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Mu\u00f1oz Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Valdez Saenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina","family":"Lomonaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thao A.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Bedossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8629-418X","authenticated-orcid":false,"given":"Kenneth","family":"Cusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2026.08.031_bib1","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2337\/dci24-0094","article-title":"Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American Diabetes Association","volume":"48","author":"Cusi","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.08.031_bib2","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1097\/HEP.0000000000001015","article-title":"Liver stiffness progression in biopsy-proven metabolic dysfunction-associated steatotic disease among people with diabetes versus people without diabetes: a prospective multicenter study","volume":"81","author":"Huang","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.eprac.2026.08.031_bib3","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2468-1253(23)00157-7","article-title":"Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis","volume":"8","author":"Huang","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.eprac.2026.08.031_bib4","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eprac.2026.08.031_bib5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/00325481.2024.2325332","article-title":"Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting","volume":"136","author":"Allen","year":"2024","journal-title":"Postgrad Med"},{"key":"10.1016\/j.eprac.2026.08.031_bib6","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"key":"10.1016\/j.eprac.2026.08.031_bib7","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic Fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.eprac.2026.08.031_bib8","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.eprac.2026.08.031_bib9","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.31014","article-title":"Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in Nonalcoholic Fatty liver disease","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.eprac.2026.08.031_bib10","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/oby.24130","article-title":"Obesity increases the risk of hepatic fibrosis in young adults with type 2 diabetes mellitus: the need to screen","volume":"32","author":"Sharma","year":"2024","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.eprac.2026.08.031_bib11","article-title":"Improving MASLD risk stratification in young adults with cardiometabolic risk factors and insulin resistance assessment","volume":"10","author":"Sharma","year":"2026","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.eprac.2026.08.031_bib12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.14309\/ajg.0000000000003455","article-title":"Association of components of metabolic syndrome and the progression of nonalcoholic fatty liver disease","volume":"121","author":"Le","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.eprac.2026.08.031_bib13","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1111\/liv.15695","article-title":"Exploring the landscape of steatotic liver disease in the general US population","volume":"43","author":"Ciardullo","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.eprac.2026.08.031_bib14","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/HEP.0000000000001311","article-title":"Population perspectives on benefits and harms of screening for metabolic dysfunction-associated steatotic liver disease","volume":"83","author":"Allen","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.eprac.2026.08.031_bib15","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jhep.2023.04.002","article-title":"Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease","volume":"79","author":"Kjaergaard","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.eprac.2026.08.031_bib16","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jhep.2025.01.014","article-title":"Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease","volume":"83","author":"Yip","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.eprac.2026.08.031_bib17","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2337\/dc20-1997","article-title":"Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening","volume":"44","author":"Lomonaco","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.08.031_bib18","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2337\/dsi23-0013","article-title":"Role of insulin resistance in the development of nonalcoholic fatty liver disease in people with type 2 diabetes: from bench to patient care","volume":"37","author":"Nogueira","year":"2024","journal-title":"Diabetes Spectr"},{"key":"10.1016\/j.eprac.2026.08.031_bib19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S2213-8587(24)00318-8","article-title":"Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment","volume":"13","author":"Stefan","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.eprac.2026.08.031_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0255535","article-title":"Baseline homeostasis model assessment of insulin resistance associated with fibrosis progression in patients with nonalcoholic fatty liver disease without diabetes: a cohort study","volume":"16","author":"Koo","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.eprac.2026.08.031_bib21","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1002\/hep.32499","article-title":"Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?","volume":"76","author":"Younossi","year":"2022","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.eprac.2026.08.031_bib22","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1002\/hep.26988","article-title":"Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis","volume":"59","author":"Bril","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.eprac.2026.08.031_bib23","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2337\/dc15-1876","article-title":"Metabolic impact of nonalcoholic steatohepatitis in obese patients with type 2 diabetes","volume":"39","author":"Lomonaco","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.08.031_bib24","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1007\/s00125-017-4340-1","article-title":"Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study","volume":"60","author":"Isokuortti","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.eprac.2026.08.031_bib25","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1210\/clinem\/dgac660","article-title":"Adipose tissue insulin resistance predicts the severity of liver fibrosis in patients with type 2 diabetes and NAFLD","volume":"108","author":"Kalavalapalli","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.08.031_bib26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/hep.27395","article-title":"The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease","volume":"61","author":"Maximos","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.eprac.2026.08.031_bib27","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease","volume":"156","author":"Eddowes","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.eprac.2026.08.031_bib28","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cgh.2018.04.043","article-title":"Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease","volume":"17","author":"Siddiqui","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.eprac.2026.08.031_bib29","doi-asserted-by":"crossref","first-page":"5100","DOI":"10.1016\/j.acra.2025.04.009","article-title":"Prospective comparison of 2D-Shear wave elastography and vibration-controlled transient elastography in assessing liver fibrosis in metabolic dysfunction-associated steatotic liver disease","volume":"32","author":"Li","year":"2025","journal-title":"Acad Radiol"},{"key":"10.1016\/j.eprac.2026.08.031_bib30","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.3390\/diagnostics15131598","article-title":"Comparing FIB-4, VCTE, pSWE, 2D-SWE, and MRE thresholds and diagnostic accuracies for detecting hepatic fibrosis in patients with MASLD: a systematic review and meta-analysis","volume":"15","author":"Wilson","year":"2025","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.eprac.2026.08.031_bib31","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jhep.2023.04.025","article-title":"An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography","volume":"79","author":"Liang","year":"2023","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.eprac.2026.08.031_bib32","article-title":"Hepatic glucose production rises with the histological severity of metabolic dysfunction-associated steatohepatitis","volume":"5","author":"Sabatini","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.eprac.2026.08.031_bib33","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jhep.2025.04.019","article-title":"Phosphatidylethanol levels distinguish steatotic liver disease subgroups and are associated with risk of major liver outcomes","volume":"83","author":"Vaz","year":"2025","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.eprac.2026.08.031_bib34","doi-asserted-by":"crossref","first-page":"7156","DOI":"10.3390\/ijms24087156","article-title":"Role of insulin clearance in insulin action and metabolic diseases","volume":"24","author":"Ghadieh","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.eprac.2026.08.031_bib35","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.2337\/dc23-1267","article-title":"Reduced insulin clearance differently relates to increased liver lipid content and worse glycemic control in recent-onset type 2 and type 1 diabetes","volume":"46","author":"Zaharia","year":"2023","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2026.08.031_bib36","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2337\/dc24-2075","article-title":"Screening for metabolic dysfunction-associated steatotic liver disease-related advanced fibrosis in diabetology: a prospective multicenter study","volume":"48","author":"Caussy","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.08.031_bib37","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eprac.2026.08.031_bib38","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eprac.2026.08.031_bib39","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/hep.25539","article-title":"Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease","volume":"55","author":"Lomonaco","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.eprac.2026.08.031_bib40","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/hep.28985","article-title":"Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease","volume":"65","author":"Bril","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.eprac.2026.08.031_bib41","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.metabol.2010.12.001","article-title":"Metabolic factors in the development of hepatic steatosis and altered mitochondrial gene expression in vivo","volume":"60","author":"Wang","year":"2011","journal-title":"Metabolism"},{"key":"10.1016\/j.eprac.2026.08.031_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104714","article-title":"Alterations of hepatic energy metabolism in murine models of obesity, diabetes and fatty liver diseases","volume":"94","author":"Dewidar","year":"2023","journal-title":"EBioMedicine"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26012887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26012887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:47:32Z","timestamp":1793911652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26012887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":42,"alternative-id":["S1530891X26012887"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.08.031","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Using Homeostatic Model Assessment of Insulin Resistance to Improve Metabolic Dysfunction-Associated Steatotic Liver Disease Risk Stratification in Individuals With Type 2 Diabetes From Primary Care and Endocrinology Settings","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.08.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}